Key result
Review weighs alternative antiplatelets against aspirin and highlights the potential of targeting platelet immune properties.
Why the study?
Although aspirin prevents cardiovascular events, not all patients benefit, prompting the development of newer anti-platelet agents that face cost-benefit and bleeding challenges.
This review provides a comprehensive overview of the evolution of anti-platelet therapies, emphasizing the ongoing challenge of balancing cardiovascular efficacy with bleeding risks and exploring future immunomodulatory targets.
Emphasizes balancing bleeding risks with efficacy in antiplatelet choices; leaves open immunomodulatory targets for future investigation.
The discovery of the role of platelets in cardiovascular disease led to the introduction of aspirin as a therapeutic agent for heart disease. Aspirin has proven to be effective in preventing cardiovascular events but the fact that not all patients benefit from aspirin has led to the search for more effective agents. Numerous agents have been discovered including thromboxane synthase inhibitors, phosphodiesterase inhibitors, GPII b/ III a antagonists, P2Y12 antagonists and PAR ‐1 antagonists. However, all faced two challenges – their cost‐benefit relationship in comparison with aspirin and the risk of bleeding that is often associated with greater efficacy. In this paper, I review the performances of these different classes of anti‐platelet agent and discuss the potential future for novel anti‐thrombotics. I also highlight the role of platelets in immunology and discuss the potential for targeting the immune properties of platelets.
No takes yet. Share an insight, caveat, or question.
Dermot Cox (2019) conducted a review in Cardiovascular disease. Anti-platelet agents vs. Aspirin was evaluated. This review discusses the performance, cost-benefit, and bleeding risks of various anti-platelet agents compared with aspirin, and highlights the potential for targeting platelet immune properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: